evidence table

Bacopa Focus Randomized Trial Evidence Table

Structured evidence table for Bacopa Focus Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Bacopa Focus Randomized TrialBacopa consumption is known to enhance cognitive performance in healthy individuals and is associated with alterations in pathways related to branched-chain and aromatic amino acid biosynthesis.2Dwivedi A (2026)Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
Bacopa Focus Randomized TrialThe cohort predominantly comprises men (53/60, 88.3%), individuals with at least a high school education (47/60, 78.3%), and participants at elevated risk for cognitive decline.2Dwivedi A (2026)Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
Bacopa Focus Randomized TrialBackground Amnestic mild cognitive impairment (aMCI) represents a transitional stage between normal aging and Alzheimer disease (AD), where early intervention is critical for preserving cognition and delaying or preventing progression to dementia.2Dwivedi A (2026)Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
Bacopa Focus Randomized TrialDue to the limited availability of curative pharmacological treatments, there is growing interest in traditional and indigenous medicinal interventions, such as Bacopa monnieri (Linn.) or Brahmi, a widely used Ayurvedic nootropic herb.2Dwivedi A (2026)Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
Bacopa Focus Randomized TrialUnder normal conditions, it is sequestered in the cytoplasm by Kelch-like ECH-associated protein 1 (Keap1), which targets it for degradation [].4Cipriano Giovanni Luca (2026)Phytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy
Bacopa Focus Randomized TrialThe following subsections provide a detailed analysis of the molecular profiles and clinical evidence for these three primary bioactives.4Cipriano Giovanni Luca (2026)Phytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy
Bacopa Focus Randomized TrialIn elderly patients with mild cognitive impairment (MCI), 16 weeks of Lion’s Mane supplementation significantly improved cognitive scores, with a subsequent decline observed once supplementation ceased, emphasizing its role in maintaining functional neural connectivity [].4Cipriano Giovanni Luca (2026)Phytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy
Bacopa Focus Randomized Trial1 2 3 4 5 6 The global increase in life expectancy has led to a parallel rise in the prevalence of neurodegenerative diseases and age-related cognitive decline [,], establishing brain health as a paramount priority in contemporary biomedical research.4Cipriano Giovanni Luca (2026)Phytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy
topicBacopa Focus Randomized Trial
claimBacopa consumption is known to enhance cognitive performance in healthy individuals and is associated with alterations in pathways related to branched-chain and aromatic amino acid biosynthesis.
evidence level2
citationDwivedi A (2026)
sourceEfficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
topicBacopa Focus Randomized Trial
claimThe cohort predominantly comprises men (53/60, 88.3%), individuals with at least a high school education (47/60, 78.3%), and participants at elevated risk for cognitive decline.
evidence level2
citationDwivedi A (2026)
sourceEfficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
topicBacopa Focus Randomized Trial
claimBackground Amnestic mild cognitive impairment (aMCI) represents a transitional stage between normal aging and Alzheimer disease (AD), where early intervention is critical for preserving cognition and delaying or preventing progression to dementia.
evidence level2
citationDwivedi A (2026)
sourceEfficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
topicBacopa Focus Randomized Trial
claimDue to the limited availability of curative pharmacological treatments, there is growing interest in traditional and indigenous medicinal interventions, such as Bacopa monnieri (Linn.) or Brahmi, a widely used Ayurvedic nootropic herb.
evidence level2
citationDwivedi A (2026)
sourceEfficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
topicBacopa Focus Randomized Trial
claimUnder normal conditions, it is sequestered in the cytoplasm by Kelch-like ECH-associated protein 1 (Keap1), which targets it for degradation [].
evidence level4
citationCipriano Giovanni Luca (2026)
sourcePhytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy
topicBacopa Focus Randomized Trial
claimThe following subsections provide a detailed analysis of the molecular profiles and clinical evidence for these three primary bioactives.
evidence level4
citationCipriano Giovanni Luca (2026)
sourcePhytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy
topicBacopa Focus Randomized Trial
claimIn elderly patients with mild cognitive impairment (MCI), 16 weeks of Lion’s Mane supplementation significantly improved cognitive scores, with a subsequent decline observed once supplementation ceased, emphasizing its role in maintaining functional neural connectivity [].
evidence level4
citationCipriano Giovanni Luca (2026)
sourcePhytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy
topicBacopa Focus Randomized Trial
claim1 2 3 4 5 6 The global increase in life expectancy has led to a parallel rise in the prevalence of neurodegenerative diseases and age-related cognitive decline [,], establishing brain health as a paramount priority in contemporary biomedical research.
evidence level4
citationCipriano Giovanni Luca (2026)
sourcePhytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy

Learn next

Related evidence and supplement guides

GuideLutein Focus Randomized Trial: What the Evidence SaysLutein Focus Randomized Trial has 2 source documents in the current Migaku evidence database. Th...GuideBacopa Memory Randomized Trial: What the Evidence SaysBacopa Memory Randomized Trial has 2 source documents in the current Migaku evidence database. T...GuideBacopa Sleep Randomized Trial: What the Evidence SaysBacopa Sleep Randomized Trial has 2 source documents in the current Migaku evidence database. Th...GuideCholine Focus Randomized Trial: What the Evidence SaysCholine Focus Randomized Trial has 2 source documents in the current Migaku evidence database. T...RankingBest Nootropics for Focus & Attention: 2026 Clinical Evidence ReviewWe separate the clinical evidence from the marketing hype, ranking the most effective brain supp...RankingBest Supplements for Focus & Concentration (Evidence-Ranked)Focus supplements are a crowded market full of hype. These five have the strongest clinical evid...RankingBest Supplements for Anxiety: Evidence-Based Rankings 2026Anxiety supplements with genuine clinical evidence include ashwagandha (strongest for chronic an...AnswerDoes Lutein Focus Randomized Trial work?Lutein Focus Randomized Trial has evidence relevant to strength of evidence and what the studies...

Source documents

  1. Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.
  2. Phytochemical and Fungal Bioactive Compounds in the “Brain Health Triad”: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy